Abstract: This disclosure features methods and compositions for treating inflammatory disorders or conditions that arise in a tissue originating from the endoderm using an immune modulator.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an IL-1 inhibitor.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof, such as glatiramer acetate).

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an IL-12/IL-23 inhibitor.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an integrin inhibitor. In an exemplary embodiment, a pharmaceutical formulation that comprises the medicaments is released from an ingestible device at a location in the gastrointestinal tract that is proximate to one or more sites of disease.

Abstract: Ingestible devices capable of delivering a dispensable substance, such as, for example, a therapeutic agent, as well as related components, systems and methods, are disclosed. A removably attachable storage reservoir configured to be used with an ingestible device and capable of storing dispensable substance, such as, for example, a therapeutic agent, as well as related components, systems and methods, are also disclosed.

Abstract: The present disclosure relates to gastrointestinal (GI) tract detection methods, devices and systems.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a SMAD7 inhibitor.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a JAK inhibitor.

Abstract: Sampling systems that include an absorbent material a preservative, such as an analyte preservative, as well as related materials and methods, are disclosed.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor.

Abstract: The disclosure provides an oral composition for reducing serum cholesterol, serum lipids, body fat, or atherogenic index or for prophylaxis or treatment of atherosclerosis, cardiovascular or cerebrovascular diseases, comprising a highly bsh active bacteria, isolate or supernatant thereof; wherein the highly bsh active bacteria degrades >50 ?mol glycodeoxycholic acid (GDCA)/gram/hour and >2 ?mol taurodeoxycholic acid (TDCA)/gram/hour when measured over 1 hour and 5 hours, respectively, or degrades >65 ?mol GDCA/g/hr and >7 ?mol TDCA/g/hr when measured over 30 minutes.

Abstract: The present disclosure relates to gastrointestinal (GI) tract detection methods, devices and systems.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a CHST15 inhibitor, to be administered via an ingestible device.

Abstract: Sampling systems that include an absorbent material a preservative, such as an analyte preservative, as well as related materials and methods, are disclosed.

Abstract: An ingestible device includes a sample chamber configured to hold a sample, the sample chamber including a base having an aperture; a fluorometer separated from the sample chamber by the sample chamber base, the fluorometer including (I) a light source configured to emit excitation light, (II) a light guide configured to guide the excitation light from the light source to the sample, (III) a photodetector configured to detect emission light generated via the interaction of the excitation light with the sample. The photodetector is configured to receive the emission light from the sample through the aperture. Additionally, the fluorometer includes (IV) an emission filter between the aperture and the photodetector, the emission filter configured to (i) transmit the emission light incident thereon, and (ii) block excitation light incident thereon. In addition, the ingestible device includes a housing that houses the sample chamber and the fluorometer.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a TLR agonist.

Abstract: Various embodiments are described herein for a recovery tool kit system including a recovery tool and an associated retrieval method for retrieving and storing an ingestible device.

Abstract: Ingestible devices with a relatively large payload volume or sample volume, as well as related components, systems and methods, are disclosed.

Abstract: Various embodiments are described herein for a device and method for an ingestible medical device with a rotatable element. In some described embodiments, the ingestible medical device includes a storage sub-unit with multiple chambers each having an opening for collecting or dispensing substances from the GI tract. The device further comprises a chamber enclosure with an access port. One of the chamber enclosure and the storage sub-unit are rotatable to allow for aligning the access port with a chamber opening. The ingestible medical device includes a sensor for positioning the access port of the chamber enclosure or the storage sub-unit as one of these elements rotates.